Business
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company’s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. “We are excited to share data highlighting NS002’s potenti
About this update from Nasus Pharma Ltd.
[{"type":"image","alt":"Nasus Pharma, Ltd.","displaySize":"","headline":null,"caption":"Nasus Pharma, Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":241,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/quoV9o_G7y0qGuyE83dEZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d","width":241,"height":136}},"lazy":false},{"type":"text","content":"TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company’s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. ","length":466,"tagName":"p"},{"type":"text","content":"“We are excited to share data highlighting NS002’s potential for superior epinephrine absorption and robust formulation stability,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “Designed as a needle-free intranasal powder, NS002 aims to deliver epinephrine more rapidly in emergency situations, and the data being presented underscore the potential advantages of the powder technology. We believe NS002 represents a unique and potentially superior differentiated epinephrine delivery option for the treatment of anaphylaxis, where seconds truly matter.”","length":567,"tagName":"p"},{"type":"text","content":"Presentation details:","length":21,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:543.297px;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Nasal epinephrine spray for anaphylaxis: which is better - powder or liquid? Nasal powder has significantly higher deposition in the nasal cavity in comparison to liquid nasal spray which could lead to enhanced blood absorption","length":227,"tagName":"p"}]},{"style":"width:127.703px;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p"}]}]},{"val":[{"style":"width:543.297px;text-align:left;vertical-alig...